Final analysis of KEYNOTE-A18 showed that pembrolizumab plus concurrent chemoradiation showed sustained PFS/OS benefits in ...

Investigators also explored the combined impact of diet and physical activity. The findings indicate that the best survival outcomes were among patients who engaged in higher levels of physical ...

Significantly longer progression-free and overall survival seen in patients with BRAF V600E mutations.

Lurbinectedin and atezolizumab performed better than atezolizumab alone as maintenance therapy for extensive-stage small cell lung cancer.

Corcept Therapeutics Incorporated (NASDAQ:CORT) said on Thursday that it presented results from its Phase 2 DAZALS study of ...